EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPREG00000002638
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSPREG00000006121
Gene Symbol: LOC103475379
3 Cross references
198 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSPREG00000016972
Gene Symbol: LOC103463031
3 Cross references
181 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSPREG00000006493
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPREG00000018373
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPREG00000020534
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPREG00000013540
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSPREG00000022283
Gene Symbol: TOP1A
1 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPREG00000012861
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPREG00000011440
Gene Symbol: F2RL3
4 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPREG00000015112
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSPREG00000013600
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).